Xi Zhuo, Zhang Rui, Zhang Furong, Ma Shuang, Feng Tianda
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Int J Gen Med. 2021 Jun 28;14:2923-2929. doi: 10.2147/IJGM.S307784. eCollection 2021.
Glioma is a primary intracranial malignant tumor with high recurrence and mortality rates. It is very important to study the prognostic factors. KLF11 can function as an oncogene or a tumor suppressor, depending on the tumor and tissue types and the cancer stage. In this study, we aimed to determine whether KLF11 expression is related to the overall survival of glioma patients.
We investigated KLF11 expression in 116 glioma patients with different grades using Western blot and immunohistochemistry assay. We analyzed the patients with different glioma grades and KLF11 expression levels by Kaplan-Meier survival curves. Independent prognostic factors for poor overall survival were identified by univariate and multivariate analyses.
There were 37 patients in KLF11 low expression group and 79 patients in high expression group. There was no difference in gender, age, tumor diameter or tumor location between two groups. The patients in KLF11 high expression group had higher ECOG score ( =0.025) and higher WHO grades ( =0.029). Western blot and immunohistochemistry assay showed KLF11 expression was significantly upregulated in glioma groups compared with normal brain tissues group ( < 0.05), and the expression in grades III-IV was significantly higher than those in grades I-II ( < 0.05). Kaplan-Meier survival curve analysis showed high KLF11 expression tended to reduce the overall survival ( < 0.05). After univariate and multivariate analyses, KLF11 expression ( =0.003) and age ( =0.007) were independent prognostic factors for poor survival in glioma patients.
KLF11 expression was increased in glioma tissues, and high KLF11 expression was associated with poor prognosis. KLF11 expression was an independent prognostic factor for poor survival in glioma patients. KLF11 may serve as a novel prognostic marker for gliomas and as a novel treatment target.
胶质瘤是一种原发性颅内恶性肿瘤，复发率和死亡率都很高。研究其预后因素非常重要。KLF11可作为癌基因或肿瘤抑制基因，这取决于肿瘤类型、组织类型和癌症分期。在本研究中，我们旨在确定KLF11表达是否与胶质瘤患者的总生存期相关。
我们采用蛋白质免疫印迹法和免疫组织化学分析法，对116例不同分级的胶质瘤患者的KLF11表达进行了研究。我们通过Kaplan-Meier生存曲线分析了不同胶质瘤分级和KLF11表达水平的患者。通过单因素和多因素分析确定总生存期差的独立预后因素。
KLF11低表达组有37例患者，高表达组有79例患者。两组在性别、年龄、肿瘤直径或肿瘤位置方面无差异。KLF11高表达组患者的ECOG评分更高（P = 0.025），WHO分级更高（P = 0.029）。蛋白质免疫印迹法和免疫组织化学分析显示，与正常脑组织组相比，胶质瘤组中KLF11表达显著上调（P < 0.05），III-IV级中的表达明显高于I-II级（P < 0.05）。Kaplan-Meier生存曲线分析显示，KLF11高表达倾向于降低总生存期（P < 0.05）。经过单因素和多因素分析，KLF11表达（P = 0.003）和年龄（P = 0.007）是胶质瘤患者生存差的独立预后因素。
胶质瘤组织中KLF11表达增加，KLF11高表达与预后不良相关。KLF11表达是胶质瘤患者生存差的独立预后因素。KLF11可能作为胶质瘤的一种新的预后标志物和新的治疗靶点。
